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A B S T R A C T
Erythropoietin (EPO), traditionally known as a hematopoietic hormone, has recently been shown to have effects be-
yond hematopoiesis such as prevention of neuronal and cardiac apoptosis secondary to ischemia and induction of neoan-
giogenesis4,5,12,13. Patients with congestive heart failure (CHF) suffer considerable morbidity and mortality despite ad-
vances in therapy. Anemia, CHF, and chronic kidney insuficiency often coexist and interact to cause or worsen each other
in the so-called cardio-renal anemia syndrome3. Treatment with EPO has shown promise in such patients. The paper re-
views a case of a successful recovery of cardiac function in a patient with a severe CHF during the treatment with EPO.
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Introduction
Considerable morbidity and mortality are still associ-
ated with congestive heart failure (CHF) syndromes, des-
pite improvement in therapy. Anemia, found in about
one-third of all cases of CHF and chronic kidney insuffi-
ciency (CKI), present in about half of all CHF cases have
been showed to be associated with heightened risk for
cardiovascular death and hospitalization in CHF1,2. The
CKI is likely to be due to the renal vasoconstriction that
often accompanies CHF and can cause long-standing re-
nal ischemia. This reduces the amount of erythropoietin
(EPO) produced in the kidney and leads to anemia. In-
creased cardiac work during a long-standing anaemia
can cause left ventricular hypertrophy (LVH), cardiac ce-
ll death through apoptosis, ultimately leading to dilata-
tion of the ventricle. Therefore, a vicious circle, termed
as the cardio renal anaemia syndrome is set up, wherein
CHF causes anaemia, the anaemia causes more CHF, and
both damage the kidneys, worsening the anaemia and
the CHF further3. Adequate treatment of anemia could
slow down the progression of both the CHF and CKI.
Erythropoietin (EPO) is haematopoietic growth fac-
tor produced in the fetal liver and the adult kidney. The
premise that EPO is required only for erythropoiesis has
initially been altered by studies using animal and in vitro
models which demonstrated the existence of EPO and its
receptor in other organs and tissues such as the brain
and heart. Some studies are suggesting possible direct
protective effect of EPO on myocardial cells by increase
in cardiac cell proliferation and reduction of myocardio-
cyte apoptosis during ischemia or reperfusion injury,
thus leading to improved left ventricular function4,5.
Even though there are several published trials which
evaluated the effects of administering EPO and/or iron
to patients with CHF, the results still remain controver-
sial. Here we present a case of an exceptionally good reco-
very of cardiac function in a patient with New York
Heart Association (NYHA) stage III/IV CHF, CKI and
anaemia, which we believe could be at least in part due to
direct effect of EPO on the myocardium.
Case Report
A 49-year old woman first presents with severe weak-
ness and fatigue, dyspnea and intolerance to even the
slightest activity. Shortness of breath appears after just a
few meters of slow walk. She is pale, obviously dyspnoic,
gasping for air, she can hardly speak, leaning with her
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palms on her knees. Her medical history reveals Paget`s
disease, dilated cardiomyopathy, arterial hypertension
and CKI. Her regular therapy taken orally consists of fu-
rosemide 250 mg, ramipril 5 mg, carvedilol 3.125 mg and
amlodipine 10 mg. Skin and visible mucosal surfaces are
pale, heart action on auscultation is regular with silent
heart sounds and holosystolic murmur over the apex and
aortic valve. Moist rales are heard widely over both lungs
on inspiration. The lower border of the liver is palpable 2
cm below the costal margin, oedema is present bilaterally
in pretibial regions and around the ankles. Blood pres-
sure is 140/90 mmHg. Electrocardiograph (ECG) shows
sinus rhythm 78/min. and signs of left ventricular strain.
Roentgenogram of the chest showed an enlarged heart
silhouette occupying more than two thirds of the chest,
with enlarged pulmonary vessels and no signs of infiltra-
tion on pulmonary fields, nor signs of fluid collections.
Echocardiographic examination showed heart dimen-
sions of LVIDd 7.22 cm, LVIDs 6.1 cm, ejection fraction of
the left ventricle of 30%, left ventricular (LV) diastolic
dysfunction type III and signs of pericardial effusion.
Initial laboratory findings were: erythrocyte count
(E) of 3.69  1012/L, hemoglobin (Hb) level of 101 g/L, he-
matocrit (Htc) 0.320, urea 15 mmol/L, creatinine 197
mmol/L, Fe 10,6 mmol/L, TIBC 52,5 mmol/L, UIBC 47,4
mmol/L.
Based on her symptoms, this patient would be classi-
fied as class III/IV according to NYHA functional classifi-
cation of CHF.
During the two weeks of hospitalization she was given
furosemide intravenously, starting with 160 mg/day, with
gradual decrease in dosage until it was substituted with
oral dose of 80 mg/day. Doses of ramipril, carvedilol and
amlodipine were unchanged throughout the hospitaliza-
tion and the follow-up period. Considering the fact that
she suffered from CKI and anaemia, she was given EPO
in the dose of 4,000 I.U. a week subcutaneously, starting
with the first week of hospitalization, in order to correct
the renal anaemia.
Subsequent laboratory controls of E, Hb, Htc, urea
and creatinine were done on a monthly basis (Table 1).
During the follow – up visits she is obviously feeling
better, she is no longer dyspnoic. She can tolerate moder-
ate physical activity without difficulties. Oedemas have
disappeared, physical findings on the lungs become nor-
mal. The dose of furosemide is lowered further to 40
mg/day, with other therapy unchanged. ECGs were un-
changed. Roentgenogram done 3 months after the initial
visit showed the reduction of the heart silhouette by
about 1/5 from its original size. Echocardiography sho-
wed heart dimensions of LVIDd 6.88 cm, LVIDs 5.84 cm,
ejection fraction of the left ventricle of 40%, LV diastolic
dysfunction type II and no signs of pericardial effusion.
After 9 months of treatment she fits into NYHA classifi-
cation of CHF class I/II.
Discussion
Although the cardiorenal anemia syndrome in conges-
tive heart failure (CHF) is an independent risk factor for
vascular morbidity and mortality, little is known about
the effect of its correction with erythropoietin (EPO) on
cardiac structure and function. So far, several different
approaches to the correction of anemia in patients with
CHF have been tested, and published results are still so-
mewhat controversial. Studies of anaemia correction wi-
th erythropoietin, though on small groups, showed prom-
ising results6–8. On the other hand, two double-blind
placebo-controlled darbepoetin (long-acting EPO analog)
studies have been published in full and neither showed
an improvement in functional capacity or consistent ef-
fect on patient reported symptoms and quality of life9,10.
Small trials showed that intravenous iron alone increa-
ses Hb, reduces symptoms, and improves exercise capa-
city in anemic patients with CHF11. More studies are
needed and certain issues, particularly the optimal he-
moglobin level, should still be resolved before recomen-
dations for anemia treatment in CHF are established.
Our patient initially presented with signs of NYHA
class III/IV CHF. After she was hemodynamically stabili-
zed with increased dose of furosemide, she was started on
EPO 4,000 I.U. a week. No other modifications of the the-
rapeutic regimen were done.
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TABLE 1
LABORATORY CONTROLS DURING 9 MONTHS
Date E Hgb Htc Urea Creatinine
01.06.2005. 3.69 101 0.320 15.0 197
14.07.2005. 3.54 115 0.371 16.1 248
16.08.2005. 3.68 104 0.322 15.8 326
28.09.2005. 3.72 108 0.328 16.5 315
19.10.2005. 3.93 113 0.344 18.4 275
14.11.2005. 3.99 112 0.347 16.9 269
14.12.2005. 3.97 112 0.354 17.3 270
12.01.2006. 3.76 110 0.336 19.7 271
16.02.2006. 3.99 112 0.347 29.8 362
After nine months of treatment her functional capa-
city improved to NYHA class I/II, echocardiography
showed improvement in both systolic and diastolic func-
tion of LV and the need for diuretic was lowered. The fact
that no significant increase in hemoglobin level was no-
ted during the follow-up led us to believe that some mec-
hanisms of direct effect of EPO on myocardial tissue ha-
ve been involved in improvement of this patient heart’s
functional ability. Despite the improvement in functional
capacity of the heart, renal function slightly deteriorated
during the course of follow-up, which could be expected
because CKI is generally thought to be a progressive dis-
order regardless of etiology.
Several in vitro studies and animal models showed
cardioprotective effects of EPO following ischemia/re-
perfusion injury without an increase in hematocrit (elim-
inating oxygen delivery as an etiologic factor in myocyte
survival and function) and demonstrating that EPO can
directly protect the ischemic and infarcted heart12. EPO
protects vascular endothelial cells from apoptosis, mobi-
lizes endothelial progenitor cells and acts as an angioge-
nic factor13. Alhtough it is impossible to draw conclusions
based on treatment of a single patient, we find this case
to be consistent with numerous currently ongoing trials
investigating direct cardioprotective and neuroprotective
effects of EPO14.
Conclusion
New approaches to the treatment of cardiovascular
diseases suggest protective effects of EPO in the ischemic
heart. EPO is now considered to have applicability in a
variety of disorders that include cerebral ischemia, myo-
cardial infarction and CHF. Anemia is increasingly recog-
nized as a common, important and treatable condition in
patients with CHF. Despite increasing knowledge of ane-
mia, as well as its co-association with chronic renal dis-
ease, advanced NYHA class and worse prognosis, there
are very few evidence-based recommendations for treat-
ment. Larger, double-blind, placebo-controlled studies
are needed and certain issues, particularly the optimal
hemoglobin level, in the treatment of CHF with EPO
should still be resolved.
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U^INAK ERITROPOETINA U BOLESNIKA S TE[KIM KONGESTIVNIM ZATAJENJEM SRCA –
PRIKAZ SLU^AJA
S A @ E T A K
Za eritropoetin (EPO), hormon dugo poznat samo kao hematopoetski faktor rasta, se pokazalo da ima ulogu i izvan
hematopoetskog sustava, poput prevencije apoptoze neurona i miokardiocita za vrijeme ishemije i poticanja neoangio-
geneze4,5,12,13. Unato~ napretku u lije~enju, pacijenti s kongestivnim zatajenjem srca (KZS) jo{ uvijek trpe zna~ajan
morbiditet i mortalitet. Anemija, kongestivno zatajenje srca i kroni~no zatajenje bubrega ~esto koegzistiraju i me|u-
sobno djeluju uzrokuju}i ili pogor{avaju}i jedno drugo u takozvanom sindromu sr~anobubre`ne anemije3. Lije~enje
EPO-om se pokazalo obe}evaju}im kod ovakvih bolesnika. U radu je prikazan slu~aj uspje{nog oporavka sr~ane funkci-
je bolesnice s te{kim kongestivnim zatajenjem srca tijekom lije~enja EPO-om.
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